Guggenheim Downgrades Seelos Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja has downgraded Seelos Therapeutics (NASDAQ:SEEL) from Buy to Neutral.

September 22, 2023 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Seelos Therapeutics has been downgraded from Buy to Neutral by Guggenheim analyst Yatin Suneja.
Analyst ratings often influence the market's perception of a stock. A downgrade from Buy to Neutral suggests that the analyst sees less upside potential, which could negatively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100